Page 18 - Labatt Brain Tumour Research Centre Annual Report 2022 to 2023

YEAR IN REVIEW
Year in Review – Currently Held Grants
Dr. Uri Tabori
Determining the cellular mechanisms of initiation and evolution of hypermutant glioma. Canadian Institutes of Health Research
Empowering next-generation researchers in perinatal and child health (ENRICH). Canadian Institutes of Health Research
U-R-Immune glioma: A pilot study investigating upfront adaptive immunotherapy approach in children, adolescent and young adult patients with replication-repair deficient high-grade gliomas. The Anticancer Fund
LOGIC: Development of a complementary diagnostic for RRD detection. Genome Canada Grant
Toward a preventive cancer vaccine for children with constitutional mismatch repair deficiency. National Cancer Institute/National Health Institute
Genomic signatures of genotoxic therapies as a cause of secondary bone marrow dysfunction and MDS/AML in pediatric low-grade glioma survivors. Meagan’s HUG (Meagan Bebenek Foundation)
Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies. Canadian Institutes of Health
Single nuclei sequencing combined with multi-omics analyses to determine the impact of cell-of-origin and immune microenvironment in medulloblastoma driven by DNA replication-repair deficiency. b.r.a.i.n.child
Molecular classification of primary CNS tumors in adolescents and young adults. C17 Research Network/Kindred Foundation
Detection and prevention of hypermutant glioma in children and young adults. Canadian Cancer Society/Canadian Institutes of Health Research/ Brain Canada
A Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway. Canadian Institutes of Health Research
The landscape of replication repair deficiency in pediatric oncology, towards a childhood cancer vaccine. Public Health Institute/Children’s Oncology Group/National Health Institute
Early detection and novel stratification of pediatric low-grade gliomas by MRI-based artificial intelligence. Canadian Cancer Society/Canadian Institutes of Health Research
Alteration of mutagenic gut microbiome for cancer prevention. SickKids Garron Family Cancer Centre
Clinical translation of novel immune-based combination therapies for paediatric hypermutant cancers. Stand Up To Cancer
Biological and pre-clinical studies to enable TIL therapy clinical trial in pediatric hypermutant cancers. V Foundation
NanoString Coutner Vantage 3D platform-based complementary diagnostic tests for precision medicine in pediatric cancers. Genome Canada
Molecular based approach to improve outcome for children and young adults with low grade glioma. Canadian Institutes of Health Research
Biological and translational implications of replication repair deficiency and hyper mutation in human cancer. Canadian Institutes of Health Research
Dr. Michael Taylor
Heterogeneity through space and time drive the clinical behaviour of childhood medulloblastoma. Canadian Institutes of Health Research
PRecision Oncology For Young peopLE (PROFYLE).
Terry Fox Research Institute
Tackling childhood brain cancer at the root to improve survival and quality of life. Genome Canada/ Canadian Institutes of Health Research – LSARP
Oxygen is poison – how incorrect modelling of the human microenvironment has impeded paediatric research. Canada Foundation for Innovation – John R. Evans Leaders Fund
Prevention and treatment of lethal metastases in group 3 medulloblastoma. National Institutes of Health
The New Roads Team – Innovative approaches to curing brain tumours. Cancer Research UK
18 IMAGINE 2021-22